| | |
| Clinical data | |
|---|---|
| Other names | MDBZ; 3,4-Methylenedioxy-N-benzylamphetamine |
| Routes of administration | Oral [1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H19NO2 |
| Molar mass | 269.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Methylenedioxybenzylamphetamine, abbreviated MDBZ, and systematically named 3,4-methylenedioxy-N-benzylamphetamine, is a drug. [1] It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). [1] MDBZ was first synthesized by Alexander Shulgin. [1] In his book PiHKAL (Phenethylamines i Have Known And Loved) , the minimum dosage is listed as 150 mg, and the duration unknown. [1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDBZ. [1]
In an episode of the British spoof documentary TV show Brass Eye , David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ. [2]
MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act. [3]